Skip to main navigation
Galectin Therapeutics Logo
  • Blog
  • What We Do
    • Galectin Proteins
    • Develop Proprietary Compounds
    • Discovery Programs
    • Intellectual Property
  • Our Pipeline
    • Pipeline Overview
    • Development Programs
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Special Consultants
    • Careers
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
    • Email Alert Subscription
  • Learn More
    • About Belapectin
    • About Galectin-3
    • About the NAVIGATE Study
    • Resources
    • Video Library
    • Publications
    • News
  • Contact Us
  • What We Do
    • Galectin Proteins
    • Develop Proprietary Compounds
    • Discovery Programs
    • Intellectual Property
  • Our Pipeline
    • Pipeline Overview
    • Development Programs
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Special Consultants
    • Careers
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
    • Email Alert Subscription
  • Learn More
    • About Belapectin
    • About Galectin-3
    • About the NAVIGATE Study
    • Resources
    • Video Library
    • Publications
    • News
  • Contact Us
Events and Presentations

Investor Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • Special Consultants
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock Information
    • Analyst Coverage
  • FAQs
  • Email Alert Subscription

Financials & Filings

Show all

2023

Second Quarter
  • Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
  • Form 10-Q

Annual Reports

Title View
  • Add Files
    2022 Form 10-K 2.1 MB
  • Add Files
    2022 Form 10-K 2.1 MB
  • Add Files
    2021 Form 10-K 946.2 KB
  • Add Files
    2021 Form 10-K 946.2 KB

Proxy Statements

There are no SEC filings available.

Form 10-K

Filing date View
Mar 30, 2023 View HTML
0001140361-23-014658.pdf
0001140361-23-014658.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Mar 31, 2022 View HTML
0001140361-22-012058.pdf
0001140361-22-012058.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Form 10-Q

Filing date View
Aug 14, 2023 View HTML
0001140361-23-039411.pdf
0001140361-23-039411.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 15, 2023 View HTML
0001140361-23-024499.pdf
0001140361-23-024499.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Galectin Therapeutics Logo - Footer

© 2023 Galectin Therapeutics Inc. – All Rights Reserved

  • Compassionate Use Policy
  • Privacy Policy
  • Terms of Use
  • Sitemap

Disclaimer: This site may contain forward-looking information.